Resiquimod (R848)

Description: Resiquimod (formerly known as R-848; S-28463; VML-600; R848, S27609) is a potent imidazoquinolinamine-based immune response modifier that acts as an agonist of the TLR 7/8 receptors (Toll-like receptor 7/8) with antiviral and antitumour activity. It can induce the levels of cytokines such as TNF-alpha, IL-6 and IFN-alpha. Resiquimod is the analogue of imiquimod (also called R-837, S-26308) with potential immunostimulatory activity. Resiquimod has been reported to dose-dependently induce cytokines including IFN, TNF, IL-1beta and IL-6 in human peripheral blood mononuclear (PBMCs). In addition, Resiquimod has been revealed to stimulate intracellular IL-1beta increased approximately 15%. The results have also been noted that both monocytes and B cells produced IFN in response to Resiquimod. On April 28, 2016, orphan designation (EU/3/16/1653) was granted by theEuropean Commission to resiquimod for the treatment of cutaneous T-cell lymphoma.

References: Nat Immunol. 2002 Feb; 3(2):196-200; J Immunol. 2003 Oct 15; 171(8):4320-8.